세계의 근경직 시장 보고서(2025년)

Muscle spasticity is a condition marked by an abnormal increase in muscle tone or stiffness that can disrupt movement and speech. It typically arises from damage to the brain or spinal cord that affects the control of voluntary muscle movements.

The main types of drugs used to treat muscle spasticity include baclofen, botulinum toxin, diazepam, dantrolene sodium, and others. These drugs can be administered via various routes, such as oral and intramuscular. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The muscle spasticity market research report is one of a series of new reports from The Business Research Company that provides muscle spasticity market statistics, including the muscle spasticity industry global market size, regional shares, competitors with muscle spasticity market share, detailed muscle spasticity market segments, market trends, and opportunities, and any further data you may need to thrive in the muscle spasticity industry. These muscle spasticity market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The muscle spasticity market size has grown strongly in recent years. It will grow from $4.19 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing investments in research and development, expansion of clinical indications, favorable regulatory approvals and reimbursement policies, increasing emphasis on adopting a multimodal approach, and increasing prevalence of multiple sclerosis.

The muscle spasticity market size is expected to see strong growth in the next few years. It will grow to $6.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing focus on developing patient-centric care, expansion of distribution channels, focus on improving quality of life, focus on developing targeted drug delivery systems, and discovery of biomarkers. Major trends in the forecast period include adoption of value-based reimbursement models, integration of artificial intelligence and machine learning technologies, adoption of telehealth and remote monitoring technologies, neurostimulation techniques, and regenerative medicine approaches.

The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. patient care by inflating prices of botulinum toxin injections and intrathecal baclofen pumps developed in France and Sweden, resulting in reduced mobility management and higher rehabilitation therapy expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of musculoskeletal disorders is expected to boost the growth of the muscle spasticity market. Musculoskeletal disorders affect the muscles, bones, and joints, often leading to pain, stiffness, and restricted movement. Factors contributing to the rise in these disorders include aging populations, sedentary lifestyles, and a higher incidence of chronic conditions. Muscle spasticity treatments aim to reduce pain, enhance mobility, prevent complications, and improve the overall quality of life and functional abilities of patients. For example, a study published by The Lancet in November 2023 estimated that 494 million people worldwide experienced musculoskeletal disorders in 2020, with a projected increase of 115% by 2050. Additionally, Amgen reported in May 2022 that fractures due to osteoporosis are expected to rise by 68%, from 1.9 million in 2018 to 3.2 million by 2040. This growing prevalence of musculoskeletal disorders is driving the muscle spasticity market.

Key players in the muscle spasticity market are focusing on developing oral suspensions to treat muscle spasms caused by conditions such as multiple sclerosis and spinal cord injuries. Oral suspensions are liquid medications with active ingredients dispersed for oral consumption. For instance, ANI Pharmaceuticals, a US-based pharmaceutical company, introduced baclofen oral suspension in April 2024. This product, a generic version of Fleqsuvy, is designed to treat muscle spasms by helping to relax the muscles in conditions such as multiple sclerosis and spinal cord injuries.

In January 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical manufacturer, acquired the baclofen franchise from Saol Therapeutics, including products such as Lioresal and Lyvispah. This $83.5 million acquisition aims to strengthen Amneal Pharmaceuticals' neurology portfolio and enhance its presence in the institutional market. It also supports Amneal's entry into the biosimilar market, with expected revenue growth from the baclofen franchise by 2025. Saol Therapeutics is a US-based company specializing in developing treatments for limb spasticity and pain related to knee osteoarthritis.

Major companies operating in the muscle spasticity market are F. Hoffmann-La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Beximco Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Revance Therapeutics Inc., Acorda Therapeutics Inc., Mylan N.V., Camber Pharmaceuticals Inc., Saol Therapeutics Inc., Zydus Cadila

North America was the largest region in the muscle spasticity market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle spasticity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The muscle spasticity market consists of revenues earned by entities by providing services such as pharmaceutical treatments, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle spasticity market also includes sales of tizanidine, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Spasticity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle spasticity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle spasticity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscle spasticity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Baclofen; Botulinum Toxin; Diazepam; Dantrolene Sodium; Other Drugs
• 2) By Route Of Administration: Oral; Intramuscular; Other Routes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Baclofen: Oral Baclofen; Intrathecal Baclofen (Pump)
• 2) By Botulinum Toxin: Botox (Botulinum Toxin Type A); Dysport (Botulinum Toxin Type A); Xeomin (Botulinum Toxin Type A); Myobloc (Botulinum Toxin Type B)
• 3) By Diazepam: Oral Diazepam; Injectable Diazepam
• 4) By Dantrolene Sodium: Oral Dantrolene; Injectable Dantrolene
• 5) By Other Drugs: Tizanidine; Clonidine; Gabapentin; Other Muscle Relaxants; Selective Serotonin Reuptake Inhibitors (SSRIs)
• Companies Mentioned: F. Hoffmann-La Roche AG; AbbVie Inc.; Abbott Laboratories; Novartis AG; Medtronic plc; Teva Pharmaceutical Industries Ltd.; Boston Scientific Corporation; Sun Pharmaceutical Industries Ltd.; Ipsen Pharma; Hikma Pharmaceuticals plc; Endo Pharmaceuticals Inc.; Lupin Pharmaceuticals Inc.; Amneal Pharmaceuticals Inc.; Mallinckrodt Pharmaceuticals; Neurocrine Biosciences Inc.; Merz Pharmaceuticals GmbH; Beximco Pharmaceuticals Ltd.; ANI Pharmaceuticals Inc.; Taj Pharmaceuticals Limited; Revance Therapeutics Inc.; Acorda Therapeutics Inc.; Mylan N.V.; Camber Pharmaceuticals Inc.; Saol Therapeutics Inc.; Zydus Cadila
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Muscle Spasticity Market Characteristics

3. Muscle Spasticity Market Trends And Strategies

4. Muscle Spasticity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Muscle Spasticity Growth Analysis And Strategic Analysis Framework

• 5.1. Global Muscle Spasticity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Muscle Spasticity Market Growth Rate Analysis
• 5.4. Global Muscle Spasticity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Muscle Spasticity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Muscle Spasticity Total Addressable Market (TAM)

6. Muscle Spasticity Market Segmentation

• 6.1. Global Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Other Drugs
• 6.2. Global Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intramuscular
• Other Routes
• 6.3. Global Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Muscle Spasticity Market, Sub-Segmentation Of Baclofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Baclofen
• Intrathecal Baclofen (Pump)
• 6.5. Global Muscle Spasticity Market, Sub-Segmentation Of Botulinum Toxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botox (Botulinum Toxin Type A)
• Dysport (Botulinum Toxin Type A)
• Xeomin (Botulinum Toxin Type A)
• Myobloc (Botulinum Toxin Type B)
• 6.6. Global Muscle Spasticity Market, Sub-Segmentation Of Diazepam, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Diazepam
• Injectable Diazepam
• 6.7. Global Muscle Spasticity Market, Sub-Segmentation Of Dantrolene Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Dantrolene
• Injectable Dantrolene
• 6.8. Global Muscle Spasticity Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tizanidine
• Clonidine
• Gabapentin
• Other Muscle Relaxants
• Selective Serotonin Reuptake Inhibitors (SSRIs)

7. Muscle Spasticity Market Regional And Country Analysis

• 7.1. Global Muscle Spasticity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Muscle Spasticity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Muscle Spasticity Market

• 8.1. Asia-Pacific Muscle Spasticity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Muscle Spasticity Market

• 9.1. China Muscle Spasticity Market Overview
• 9.2. China Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Muscle Spasticity Market

• 10.1. India Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Muscle Spasticity Market

• 11.1. Japan Muscle Spasticity Market Overview
• 11.2. Japan Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Muscle Spasticity Market

• 12.1. Australia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Muscle Spasticity Market

• 13.1. Indonesia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Muscle Spasticity Market

• 14.1. South Korea Muscle Spasticity Market Overview
• 14.2. South Korea Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Muscle Spasticity Market

• 15.1. Western Europe Muscle Spasticity Market Overview
• 15.2. Western Europe Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Muscle Spasticity Market

• 16.1. UK Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Muscle Spasticity Market

• 17.1. Germany Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Muscle Spasticity Market

• 18.1. France Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Muscle Spasticity Market

• 19.1. Italy Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Muscle Spasticity Market

• 20.1. Spain Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Muscle Spasticity Market

• 21.1. Eastern Europe Muscle Spasticity Market Overview
• 21.2. Eastern Europe Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Muscle Spasticity Market

• 22.1. Russia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Muscle Spasticity Market

• 23.1. North America Muscle Spasticity Market Overview
• 23.2. North America Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Muscle Spasticity Market

• 24.1. USA Muscle Spasticity Market Overview
• 24.2. USA Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Muscle Spasticity Market

• 25.1. Canada Muscle Spasticity Market Overview
• 25.2. Canada Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Muscle Spasticity Market

• 26.1. South America Muscle Spasticity Market Overview
• 26.2. South America Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Muscle Spasticity Market

• 27.1. Brazil Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Muscle Spasticity Market

• 28.1. Middle East Muscle Spasticity Market Overview
• 28.2. Middle East Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Muscle Spasticity Market

• 29.1. Africa Muscle Spasticity Market Overview
• 29.2. Africa Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Muscle Spasticity Market Competitive Landscape And Company Profiles

• 30.1. Muscle Spasticity Market Competitive Landscape
• 30.2. Muscle Spasticity Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

31. Muscle Spasticity Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Boston Scientific Corporation
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Ipsen Pharma
• 31.5. Hikma Pharmaceuticals plc
• 31.6. Endo Pharmaceuticals Inc.
• 31.7. Lupin Pharmaceuticals Inc.
• 31.8. Amneal Pharmaceuticals Inc.
• 31.9. Mallinckrodt Pharmaceuticals
• 31.10. Neurocrine Biosciences Inc.
• 31.11. Merz Pharmaceuticals GmbH
• 31.12. Beximco Pharmaceuticals Ltd.
• 31.13. ANI Pharmaceuticals Inc.
• 31.14. Taj Pharmaceuticals Limited
• 31.15. Revance Therapeutics Inc.

32. Global Muscle Spasticity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscle Spasticity Market

34. Recent Developments In The Muscle Spasticity Market

35. Muscle Spasticity Market High Potential Countries, Segments and Strategies

• 35.1 Muscle Spasticity Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Muscle Spasticity Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Muscle Spasticity Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer